Personalizing Precision Medicine highlights the triumphs and challenges of precision medicine on a global scale.
EY-Parthenon explores how consumer products companies can play, execute, and win when expanding internationally.
Read about how to help maximize shareholder value in the EY 2018 Global Corporate Divestment Study.
EY-Parthenon’s life science article in PM360 explores the year ahead for new potential product launches for oncology, neurology, and rare blood disorders.
How can M&A deal with today’s demands while activating your digital tomorrow? Our latest report reveals what defines M&A success.
Having online offerings is no longer a “nice to have” – in today’s challenging and increasingly competitive marketplace, it has rapidly become a “must have.”
Explore the underlying forces of winning strategies in the consolidating contract development and manufacturing organization (CDMO) market.
The EY-Parthenon team is committed to bringing unconventional yet pragmatic thinking together with our clients’ smarts to deliver actionable strategies for real impact in today’s complex business landscape.